# US 2025/0144043 A1 · Methods of assessing cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144043 A1
- Document ID: US20250144043A1
- Status: Published application
- Kind: A1
- Application number: 18/837,265
- Filed: 2023-02-10
- Published: 2025-05-08
- Earliest claimed: 2022-02-11
- Assignees: Washington University
- Applicants: Washington University
- Inventors: Jose Zevallos; Aadel Chaudhuri; Craig Buchman
- Web page: https://patentgrep.com/patent/US20250144043A1

## CPC

- A61K 9/5176: {Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K9/5123)}
- A61P 35/00: Antineoplastic agents
- A61K 31/711: Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- A61K 31/712: Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
- A61K 35/76: Viruses; Subviral particles; Bacteriophages
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- A61K 39/12: Viral antigens
- A61K 2039/5152: {Tumor cells}
- A61K 2039/585: {wherein the target is cancer}
- C12N 2710/20021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2710/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Among the various aspects of the present disclosure is the provision of compositions and methods for treating cancer and sensitizing cancer or tumors to treatments. An aspect of the present disclosure provides for a method of preventing treatment resistance in non-HPV-associated cancer comprising administering a pharmaceutical composition comprising HPV-associated DNA (e.g., HPV-associated exosomes). Another aspect of the present disclosure provides for a method of increasing response to cancer treatment, optionally, surgery, radiation therapy, and chemotherapy in a subject having, suspected of having, being treated for, having previously been treated for, or diagnosed with cancer comprising administering a pharmaceutical composition comprising HPV-associated DNA (e.g., HPV-associated exosomes).

## Claims

### Claim 1

A method of preventing treatment resistance in non-HPV-associated cancer comprising administering a pharmaceutical composition comprising HPV-associated DNA (e.g., HPV-associated exosomes), wherein the pharmaceutical composition comprising HPV-associated DNA (e.g., HPV-associated exosomes) carry HPV DNA to a subject having, suspected of having, being treated for, having previously been treated for, or diagnosed with cancer.

### Claim 2

A method of increasing response to cancer treatment, optionally, surgery, radiation therapy, and chemotherapy in a subject having, suspected of having, being treated for, having previously been treated for, or diagnosed with cancer comprising administering a pharmaceutical composition comprising HPV-associated DNA (e.g., HPV-associated exosomes), wherein the pharmaceutical composition comprising HPV-associated DNA (e.g., HPV-associated exosomes) carry HPV DNA to a subject having, suspected of having, being treated for, having previously been treated for, or diagnosed with cancer.

### Claim 3

The method of any one of the preceding claims, wherein the cancer is an HPV-negative cancer, head or neck cancer, or both.

### Claim 4

The method of any one of the preceding claims, wherein the HPV-associated exomes are synthetic or exosomes derived from patients with HPV-positive oropharyngeal cancer.

### Claim 5

The method of any one of the preceding claims, wherein the HPV-associated exomes are harvested from a biological fluid, wherein the biological fluid is optionally obtained from a surgical drain harboring HPV oncogene DNA.

### Claim 6

The method of any one of the preceding claims, wherein the HPV-associated exomes are taken up by HPV-negative head and neck cancer.

### Claim 7

The method of any one of the preceding claims, wherein the HPV-associated exomes are in contact with HPV-negative cancer cells, the HPV-negative cancers behave more like HPV-positive cancers.
